Banner - NPPA Connect
Opinion|Videos|December 16, 2024

Demographics and Baseline Characteristics Across Spesolimab Dose Groups

Key Takeaways

Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.